A sweeping analysis of more than 21,500 FDA adverse event reports has mapped which anticancer drugs most strongly trigger hand-foot...

A dual PI3K/mTOR inhibitor, VDC597, suppresses signaling, kills canine lymphoma and leukemia cells in vitro, and synergizes with dexamethasone, according...

New preclinical research shows that the ATR inhibitor ceralasertib (AZD6738) synergistically restores and amplifies the antitumor activity of trifluridine in...

The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and...

A new Nature Protocols paper details a mussel-inspired dopamine polymerization technique that coats living bacteria with therapeutic molecules to combat...

A comprehensive new CACA guideline standardizes the assessment, pharmacological treatment, and minimally invasive management of adult cancer pain through a...

A new review maps the laboratory models—from organoids to humanised mice to computational pipelines—that could finally bring personalised treatment to...

A Japanese study finds that two simple postoperative blood markers can identify which patients over 70 with stage III colorectal...

New research shows that CD55 acts as a self-sufficient ignition switch for natural killer cell attack on tumors, and that...

Six emerging cancer researchers outline in a Nature Reviews Cancer anniversary viewpoint the technologies and paradigms that will shape oncology...